The global immunotherapy drugs market is anticipated to grow at a CAGR of 9.0% during the forecast period. The increasing clinical trials to develop more immunotherapy drugs is a key factor driving the growth of the market. For instance, in July 2022, Sosei Group Corp., an international biopharmaceutical company and Cancer Research UK, the world’s largest private funder of cancer research signed an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial. Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.
Browse the full report description of “Immunotherapy Drugs Market Size, Share & Trends Analysis Report, By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins, and Others), By Therapeutic Application (Cancer, Infectious Diseases, Autoimmune & Inflammatory, Other), By End-User (Hospitals, Clinics, Others), Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/immunotherapy-drugs-market
Sosei Heptares will be responsible for CTA enabling activities, including GLP toxicology, IMP manufacture1 and other necessary pre-clinical studies in preparation for the opening of the clinical trial. Sosei Heptares holds a license to the results generated under the trial to continue the clinical development and commercialization of HTL0039732. HTL0039732 has been proposed for a range of cancers including microsatellite stable3 colorectal, gastroesophageal, head and neck and castration- resistant prostate cancer.
In July 2022, Immunocare Holdings plc, a UK-based, commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases including cancer, autoimmune and infectious diseases, announced that its first patient has received new immunotherapy drug for HIV in the clinical trial. These clinical trials are offering an opportunity for the growth of the global immunotherapy drugs market.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Therapeutic Application
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- F. Hoffman L-Roche Ltd., Pfizer Inc., and Merck & Co., Inc., among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Immunotherapy Drugs Market Report by Segment
By Type
By Therapeutic Application
By End-User
Global Immunotherapy Drugs Market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/immunotherapy-drugs-market